|
Forest Laboratories, Inc.
|
909 Third Avenue
New York, NY 10022-4731
United States |
| Tel: |
1/212/421-7850 |
| URL: |
http://www.frx.com |
|
 |
| Primary Symbols & Exchanges: |
| FRX - New York Stock Exchange |
|
|
| Primary Industry: |
| Business Services |
|
|
SIC Industry Code:
|
|
NAICS Industry Code:
|
|
Thomson Financial Business Description:
| The Group's principal activities are to develop, manufacture and sell ethical drug products, which require physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter. The products consist of ethical drug specialties marketed to physicians by the Group's Forest Pharmaceuticals, Forest Therapeutics, Forest Healthcare and Forest Specialty Sales salesforces. The products of the Group include Lexapro, SSRI for the treatment of major depression and GAD; Namenda, NMDA antagonist for the treatment of Alzheimer's disease; Benicar, for the treatment of hypertension, and Campral, for the maintenance of alcohol abstinence. The major customers of the Group are McKesson Drug Company, Cardinal Health, Inc. and AmerisourceBergen Corporation. The Group operates in the United States, the United Kingdom, Ireland and Netherlands. On 10-Jan-2007, the Group acquired Cerexa, Inc. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on Forest Laboratories, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
